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ABSTRACT 
Multifunctional electrospun scaffolds were prepared from two PLA grades having 
slightly different D-lactide content (4.2 wt-% and 2.0 wt-%). Triclosan (TCS), 
ketoprofen (KTP) and p-coumaric acid (CUM) were selected as bactericide, anti-
inflammatory and antioxidant agents, respectively. Single, binary and ternary drug-
loaded microfibers having a unimodal diameter distribution could be prepared using a 
common chloroform:acetone:dimethylsulfoxide mixture and similar operational 
parameters (i.e. voltage, flow rate and tip-collector distance). FTIR spectra were 
sensitive to the low amount of drugs loaded and even showed slight differences in PLA 
conformation. DSC heating scans clearly demonstrated the ability of electrospinning to 
induce molecular orientation of PLA and also the nucleation effect of incorporated 
drugs to induce crystallization. Thus, crystallinity of binary drug-loaded scaffolds was 
significantly higher than observed for unloaded samples.  
Release behavior of the three drugs from loaded scaffolds and PLA matrices in 
PBS:ethanol medium was evaluated. A rapid release was always detected, together with 
partial drug retention which was higher when the more stereoregular PLA matrix was 
employed. A strong bactericide effect was found when scaffolds were loaded with 3 
w/v-% of TCS, but incorporation of a small percentage of KTP (i.e. 1 w/v-%) had a 
bacteriostatic effect even in the absence of TCS. The inherent cytotoxicity of TCS could 
be well neutralized by enhancing cell viability by incorporation of CUM and/or KTP. 
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INTRODUCTION 
 
The development of scaffolds that could mimic natural tissues is a basic point for tissue 
engineering and regenerative medicine applications. These scaffolds can be specifically 
prepared to display biological activities that induce regeneration of both tissues and 
organs and restore the function of diseased or traumatized tissues in the human body.1 
Scaffolds are defined as three-dimensional porous solid biomaterials which should offer 
a unique combination of inherent properties, such as to provide physical stability at the 
implanted injury site. Besides promoting tissue regeneration, scaffolds have other very 
important characteristics/functions: (i) ability to favor cell-biomaterial interactions (i.e. 
cell adhesion and extracellular matrix (ECM) deposition); (ii) enhancement of cell 
survival (proliferation and differentiation); (iii) comparability of biodegradation rate 
with required time for tissue regeneration, and (iv) ability to cause minimum 
inflammation or toxicity in-vivo resulting from toxic metabolic byproducts.1 In 
addition, scaffolds can be used as carriers and/or delivery systems of drugs or 
biomolecules to palliate different stages during replacement and regeneration of tissue 
or to avoid rejection of implanted biomaterial. 
Natural and synthetic polymers have been widely used as biomaterials for medical 
devices and tissue-engineering scaffolds.2,3 The most commonly used synthetic 
polymers in tissue engineering are polylactide (PLA), polyglicolide (PGA) and their 
copolymers (PLGA).4 These materials provide synthetic scaffolds characterized by 
excellent mechanical properties, highly interconnected porous structure, ability to 
activate their surfaces to yield specific chemical properties, and geometry adapted to 
direct tissue regeneration.5 
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Different techniques to prepare scaffolds are currently available, but electrospinning is 
probably one of the simplest processes to obtain porous matrices constituted by fibers in 
the micrometer and nanometer scales. Furthermore, since fibers can be easily loaded 
with drugs during their preparation, electrospinning provides the most promising results 
for tissue engineering, tissue regeneration and drug delivery applications.6,7 
Specifically, electrospun scaffolds can be used for musculoskeletal tissue engineering 
including bone and cartilage, and also as control delivery systems for drugs, proteins 
and DNA.8 Electrospinning has been widely applied to obtain scaffolds from natural 
polymers such as collagen,9 gelatin,10 chitosan,11 HA,12 and silk fibroin, 13  as well as 
synthetic polymers like polylactide,14 polyurethane,15 polycaprolactone,16 poly(lactide-
co-glicolide),17 polyvinilalcohol,18 and poly(lactide-co-caprolactone).5 Furthermore, 
electrospinning is a suitable technique for processing mixtures of polymers to get 
materials that combine the properties of the individual components. For example, 
combination of biodegradable and conducting/electroactive polymers is receiving 
nowadays great attention to give rise to advanced materials for local stimulation of 
tissues or the stimulation of either the proliferation and differentiation of cells.19,20  
Several health problems have been associated with the use of biomaterials, for example 
infection related to the use of catheters21 or prosthetic bones, among others.22 Other 
problems concerning damaged tissue, such as inflammation produced by cell necrosis, 
must be considered, too. Inflammation and oxidative stress are two cellular processes in 
the tissue that must be treated to restart rapid recovery from tissue injury. In this sense, 
scaffolds should be designed to be used not only as appropriate platforms to support cell 
proliferation but also as active elements to mediate cell recovery through local tissue 
medication. 
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Great efforts have been focused to the development of antibacterial nanofibers through 
electrospinning.23 Different systems have specifically been considered taking into 
account the substrate polymer (e.g., polylactide and polycaprolactone), the antibacterial 
agent (e.g., antibiotic, bactericide, silver and metal oxide nanoparticles and chitosan) 
and the selected method to incorporate the drug (e.g., incorporation of the agent in the 
electrospinning solution, coaxial electrospinning, conversion of a precursor to its active 
form by a post-treatment, previous encapsulation of the antibacterial agent and 
attachment of the active agent onto the fiber surface). Triclosan is probably one of the 
most employed bactericide agent as indicated in Table 1. 
[TABLE 1] 
A problem concerning the use of biodegradable polymers (e.g., PLA) is that their 
degradation products often cause severe foreign body reaction and an inflammatory 
response. Different non-steroidal and anti-inflammatory drugs like ibuprofen or 
ketoprofen have long been used (Table 1) to improve performance of electrospun 
scaffolds. A clear advantage of electrospinning is the possibility to incorporate these 
poorly soluble drugs into the fibrous matrix system. 
In recent years, the stress oxidative has been identified as a cause of several human 
diseases, so the application of antioxidants as therapeutic agent has an increased interest 
for the medical treatment. The biological system has a proper balance between the 
formation and removal of the reactive oxygen species. Also, transplantation of organ 
and tissues has more success when stress oxidative is reduced by the administration of 
molecules with antioxidant activity.24,25 Although there are very few reports about of 
devices and scaffolds loaded with antioxidants, some of them merit attention, e.g. those 
concerning mats of electrospun cellulose acetate fibers containing asiaticoside or 
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curcumin,26 vitamin A acid or vitamin E,27 as well as polyesters like polycaprolactone 
and polylactide loaded with curcumin,28 and gallic acid,29 respectively. Furthermore, 
polylactide (PLA) has also been loaded with vitamin B6 and hydroxycinnamic acids 
(e.g., p-coumaric and caffeic acids).30 Thus, new electrospun fibers matrices loaded with 
antioxidant molecules can reduce pro-oxidative damage in cells grown onto these 
materials (Table 1). The presence of a high amount of reactive oxygen species in an 
injured tissue generates a harmful environment, which could cause a rejection of the 
biomaterial. In conclusion, scaffolds functionalized with antioxidants can be used as 
platforms for tissue engineering.30 
Electrospinning is a simple and cost-effective technique that could be employed to get 
multifunctional scaffolds by the simultaneous load of appropriate agents. Incorporation 
of bactericide agents and growth factors is for example highly interesting to develop 
wound dressings able to treat infection and healing chronic wounds.31 Despite this great 
potential, scarce works refer to preparation of multifunctional systems. In particular 
ternary systems based on bactericide, anti-inflammatory and antioxidant agents have not 
been considered up to now at the best of our knowledge. 
TCS has a well demonstrated antimicrobial activity against both for Gram-negative and 
Gram-positive bacteria. Thus, TCS has been extensively used for topical applications, 
and its controlled release from biomaterials evaluated.30,34 CUM is an hydroxycinnamic 
acid with a recognized activity as scavenger for the prevention of the oxidative stress 
damage produced by free radicals.35,36 KTP is a non-steroidal anti-inflammatory drug 
(NSAID) used to control pain and inflammation in rheumatic diseases, being also 
effective as an anti-inflammatory agent in humans with flogistic diseases.37,38 
[FIGURE 1] 
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The goal of this work is the preparation of multiactive electrospun scaffolds that could 
represent an improved material for the regeneration and repair of a damaged tissue. 
Specifically avoid rejection, palliate possible bacterial activity and possible 
inflammation during the tissue regeneration. To this end, triclosan (TCS), p-coumaric 
acid (CUM) and ketoprofen (KTP) drugs (Figure 1) with antimicrobial, antioxidant, 
anti-inflammatory activities, respectively, will be loaded to two polylactide (PLA) 
grades having a slightly different stereoregularity and consequently thermal, 
degradation and mechanical properties.32,33 The scaffold morphology, physicochemical 
properties, drug release profiles, antimicrobial activity and biocompatibility of scaffolds 
are presented.  
EXPERIMENTAL 
 
Materials 
Two commercial PLA grades from Natureworks® differing on the lactic acid content 
were used. Specifically, PLA 2002D and PLA 4032D samples having 95.8 and 98 wt-% 
of L-lactic were selected. PLA 2002D is a transparent solid with a density of 1.24 g/cc, 
being its calorimetric and mechanical properties defined by a glass transition 
temperature (Tg) of 58 ºC, a melting point (Tm) of 153 ºC, a tensile modulus (E) of 3500 
MPa, a tensile strength () of 53-60 MPa and a tensile elongation () of 6%. PLA 
4032D has a translucent appearance, a density of 1.24 g/cc and highly different 
properties from those of the sample with higher D content. Thus, Tg, Tm, E,  and  
values were reported to be 70 ºC, 160 ºC, 3440-3784 Ma, 103.2-144.5 MPa and 100-
180%, respectively. Molecular weights determined by GPC were quite similar, and 
specifically Mn, Mw and polydispersity index were 98,100 g/mol, 181,000 g/mol and 
1.85 for PLA 2002D and 84,200 g/mol, 179,400 g/mol and 2.13 for PLA 4032D.32,63 
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Trichloromethane (or chloroform), acetone, dimethylsulfoxide (DMSO), triclosan 
(IrgasanTM) (TCS), ketoprofen (KTP) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, USA) 
and p-coumaric acid (CUM) was purchased from Acros Organics (New Jersey, USA). 
VERO (African green monkey kidney epithelial cells) and MDCK (Madin-Darby 
canine kidney epithelial cells) were purchased from ATCC (USA). Escherichia coli 
CECT 101 and Micrococcus luteus CECT 245 bacteria strains were obtained from the 
Spanish Collection of Type Culture (Valencia, Spain). 
 
Preparation of fibers by electrospinning 
Both PLA 2002D and PLA 4032D (1 g) were dissolved in 9 mL of a chloroform-
acetone mixture (2:1 v/v). Subsequently, drugs were dissolved in 1 mL of 
dimethysulfoxide (DMSO) that was added to the polymer solution. The mixture was 
homogenized by vortex to obtain an electrospinable solution of 10 w/v-% PLA, and 3 
w/v-% TCS, 1 w/v-% KTP and 1 w/v-% CUM. Furthermore, PLA samples loaded with 
one single drug and dual-drug combinations (i.e. TCS/CUM and KTP/CUM) were also 
prepared as controls. 
A plastic syringe of 5 mL (Becton Dickson, Spain) was filled with the corresponding 
solution containing PLA and the selected combination of drugs. Electrospinning was 
carried out between the needle (18G; Terumo, Belgium) connected to the anode and the 
static collector connected to the cathode, being the needle-collector distance optimized. 
A high voltage supply (Gamma High Voltage Research, ES30-5W) was employed. All 
electrospinning experiments were conducted at room temperature (approx. 25ºC). 
 
Morphology and crystallinity of drug loaded PLA nanofibers 
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Diameter measurements and inspection of fiber surfaces were performed by scanning 
electron microscopy using a Focus Ion Beam Zeiss Neon 40 instrument (Carl Zeiss, 
Germany). A Mitec K950 Sputter Coater equipped with a film thickness monitor k150x 
was used to coat the samples. Samples were viewed at an accelerating voltage of 5 kV.  
Thermal properties were determined by differential scanning calorimetry with a TA 
Instruments Q100 series equipped with a refrigeration cooling system (RCS). 
Experiments were conducted under a flow of dry nitrogen with a sample weight of 
approximately 5 mg and calibration was performed with indium. Heating and cooling 
runs were carried out at a rate of 20 ºC/min and 10 ºC/min, respectively. 
FTIR spectra of unloaded and drug loaded PLA 4032D and PLA 2002D samples were 
recorded on a Jasco FTIR 4100 spectrophotometer dotted with an attenuated total 
reflection accessory (Specac MKII Golden Gate Heated Single Reflection Diamond 
ATR). 
 
Release experiments 
Controlled release experiments were performed with electrospun scaffolds cut into 
small square pieces (20 x 20 x 0.1 mm3). These samples were weighed and placed into 
polypropylene tubes. A typical phosphate buffered saline (PBS) supplemented with 70 
v/v-% of ethanol and PBS with 10 v/v-% of serum were used as a release media. In 
addition, PBS was also considered as a control. The first medium was selected since is 
economical, allows an easy detection of the delivered drug (e.g. by UV-Vis 
spectroscopy) and may favour the release of hydrophobic drugs due to the incorporation 
of ethanol that in addition can diffuse within the polymer bulk. In this way, differences 
between the studied systems (e.g. influence of crystallinity of PLA matrices or type of 
loaded drug) can be highlighted using this system. Moreover, ethanol-saline mixtures 
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were previously employed to simulate the usual serum supplemented medium, being 
found a good agreement for low ethanol content (i.e. 5%-25%) and drugs only loaded in 
surface-coatings.33  
Drug release was carried out in 50 mL of the release medium at 25 ºC for 1 week. Drug 
concentration in both PBS-ethanol and PBS release media was evaluated by UV-Vis 
spectroscopy using a UV-3600 spectrophotometer (Shimadzu, Japan). Calibration 
curves were obtained by plotting the absorbance measured at the corresponding 
wavelengths against drug concentration. Specifically, measurements were performed at 
wavelengths of 257, 281 and 310 nm for KTP, TCS and CUM, respectively.  Samples 
(1 mL) were drawn from the release medium at predetermined intervals and an equal 
volume of fresh medium was added to the release vessel. The amount of drug remaining 
in the scaffold was also determined by absorbance measurements. In this case, the 
sample was dissolved in chloroform and the drug subsequently extracted with ethanol. 
All the drug release tests were carried out using three replicates to control release 
homogeneity, and the results obtained from the samples were averaged. 
In the case of a serum supplemented release medium scaffolds were removed after the 
selected exposure time, extensively washed with water, dried and finale dissolved in 
chloroform. The amount of remaining drug was again determined by UV-Vis 
measurements at the corresponding wavelengths.   
 
Antimicrobial test: assay of bacterial growth and adhesion 
The antimicrobial effect of electrospun scaffolds loaded with CUM, TCS/CUM, 
KTP/CUM and TCS/KTP/CUM was evaluated using both Gram-negative (Escherichia 
coli) and Gram-positive (Micrococcus luteus) bacteria. The bacteria were previously 
grown aerobically to exponential phase in broth culture (5 g/L beef extract, 5 g/L NaCl, 
10 g/L peptone, pH 7.2). 
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Growth experiments were performed in tubes of 15 mL. 103 CFU (colony forming 
units) were seeded in 5 mL of broth culture containing the corresponding electrospun 
scaffolds. The cultures were incubated at 37 ºC and agitated at 80 rpm. After incubation 
for 24 and 48 h, an aliquot of 100 µL was diluted 10 times with distilled water. UV 
absorbance was measured at 600 nm and the bacterial number was determined using a 
McFarland curve scale. The relative growth (percentages) was graphically represented. 
107-108 CFU were seeded in 5 mL of broth culture containing the corresponding 
electrospun scaffolds to perform the adhesion measurements. The cultures were 
incubated at 37 ºC and agitated at 80 rpm. After incubation, the cultures were aspired 
and the material washed once with distilled water. Subsequently, 1 mL of sterile 0.01 M 
sodium thiosulfate was added. The mixture was vortexed for 2 min and left to repose for 
30 min in order to remove the bacteria. Finally, 4 mL of broth culture was added and the 
tubes were incubated at 37 ºC for 24 h and agitated at 80 rpm. The bacterial number was 
determined as above indicated. 
All assays were performed in triplicate and the results averaged. ANOVA followed by 
Tukey test were conducted as statistical analyses at a confidence level of 95 % (p<0.05). 
 
 
In-vitro biocompatibility assays: cell adhesion and proliferation 
MDCK and VERO cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 2 
mM L-glutamine at 37ºC in a humidified atmosphere with 5% CO2 and 95% air. The 
culture medium was changed every two days and, for sub-culture, cell monolayers were 
rinsed with phosphate buffered saline (PBS) and detached by incubation with trypsin-
EDTA (0.25%) at 37ºC for 2-5 min. Cell concentration was determined by counting 
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with a Neubauer chamber and employing 4% trypan-blue as dye vital. Detached cells 
with viability ≥ 95% were used for biocompatibility assays. 
Square pieces (10  x  10  x  0.1 mm3) of both unloaded and drug-loaded PLA electrospun 
microfibers were cut to perform biocompatibility assays. These pieces were placed into 
the wells of a multi-well culture plate and sterilized by UV-radiation in a laminar flux 
cabinet for 15 min. To fix the samples in the well, a small drop of silicone (Silbione® 
MED ADH 4300 RTV, Bluestar Silicones France SAS, Lyon, France) was used as the 
adhesive. Samples were incubated in 1 mL of the culture medium under culture 
conditions for 30 min to equilibrate the material. Finally, the medium was aspired and 
the material was evaluated for cell adhesion and proliferation by exposing cells to direct 
contact with the material surface. 
To assess cell adhesion, aliquots of 50-100 µL containing 5x104 cells were seeded in the 
wells containing the electrospun scaffolds. The plate was incubated in culture 
conditions for 30 min to allow cell attachment to the material surface. Then, 1 mL of the 
culture medium was added to each well and the plate was incubated for another 24 h. 
Finally, cell viability was determined by the MTT assay. Unloaded PLA scaffolds and 
samples loaded with 3 w/v-% of TCS were used as positive controls and negative 
controls, respectively. 
Cell proliferation was evaluated by a similar procedure to the adhesion assay, but the 
aliquot of 50-100 µL contained only 2x104 cells and the cultures were maintained for 7 
days to allow cell growth and adequate cell confluence in the well. The medium was 
renewed every two days. Finally, cell viability was determined by the MTT assay. 
Each sample was evaluated using five replicates and the results were averaged and 
graphically represented. The statistical analysis was performed by one-way ANOVA to 
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compare the means of all groups; Tukey test was then applied to determine a 
statistically significant difference between two studied groups. The tests were 
performed with a confidence level of 95% (p < 0.05). 
 
RESULTS AND DISCUSSION 
Morphology of PLA multifunctional electrospun scaffolds  
The success of electrospinning process requires strict control of the operational 
parameters of each polymer (e.g., strength of the applied electrical field, tip-collector 
distance, flow rate) and solution properties (e.g., viscosity, surface-tension, dielectric 
constant, volatility, concentration).64,65 Selection of an appropriate solvent system 
probably becomes one of the most crucial points, especially when compounds of highly 
different characteristics (e.g. polylactides samples and the above selected drugs) must 
be electrospun.66 Note, for example, the large difference between reported Hildebrand 
parameters for PLA67 (i.e., 9.87 (cal/cm3)0.5) and TCS68 (i.e., 14.38 (cal/cm3)0.5). In 
addition, a relatively high polymer concentration is required to avoid formation of drops 
or beads49 and obtain continuous fibers in a micrometer scale, which appears more 
appropriate for a sustained drug release. These factors focused us to select a 
chloroform:acetone:dimethylsulfoxide mixture with a 6:3:1 v/v/v ratio; specifically, the 
two first solvents were appropriate to obtain PLA electrospun microfibers,34 whereas 
the third solvent was essential to allow dissolution of the three selected drugs (TCS, 
CUM and KTP).  
With regard to operational parameters, the selection of the spinning voltage (15 kV) was 
essential to ensure the formation of continuous and regular fibers and a minimum 
amount of beads. The distance between the target and the syringe tip was kept close to 
12.5 cm, and the flow rate was found to be drastically affected by the viscosity of the 
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final solution. Thus, a flow rate of 10 mL/h was chosen except when the three drugs 
dissolved simultaneously. In this case, it was necessary to reduce the flow rate to 5 
mL/h due to increased viscosity of the final solution.  
Figure 2 shows low magnification SEM images of electrospun fibers obtained under the 
selected conditions for the different PLA grades and loaded drugs (in particular, single, 
binary and ternary drug-loaded scaffolds with CUM as the common drug). Analysis of 
these images revealed that fibers always had a unimodal Gaussian diameter distribution 
(Figure 3) with average diameters between 1.7 µm and 3.8 µm as summarized in Table 
2. The observed variations in the diameter size can be summarized as follows: a) 
Microfibers prepared from the more stereoregular PLA 4032D sample always had 
smaller diameters than determined for PLA 2002D compared to fibers with a similar 
drug load; b) incorporation of CUM gave rise to a significant diameter increase (e.g. 
from 1.86 to 3.85 nm and from 1.66 to 2.14 nm for single drug-loaded PLA2002D and 
PLA 4032D samples, respectively), which seemed more significant when the more 
amorphous PLA grade was employed; c) binary drug-loaded samples showed a 
diameter decrease compared to single drug-loaded fibers, with the effect being less 
pronounce upon addition of TCS. Note, , in addition, that the percentage of loaded TCS 
was higher than that of KTP (i.e. 3 w/v-% as opposed to 1 w/v-%), and d) the diameter 
of ternary drug-loaded samples increased compared to unloaded samples, as above 
indicated, but the trend was not clear since flow rate conditions were changed. In 
summary, the presence of drugs modified the physicochemical characteristics of the 
dissolution (e.g. viscosity was seriously affected in ternary TCS/KTP/CUM loaded 
mixtures in such a way that the flow rate had to be modified) and influenced the 
morphology of electrospun samples significantly even when processed under the same 
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set of operational parameters. The obtained results suplement those previously 
described in the single loaded systems given in Table 1. 
[FIGURE 2] 
[TABLE2] 
[FIGURE 3] 
 
Texture of microfibers was slightly different depending on the loaded drugs as shown in 
the high magnification SEM micrographs of Figure 4. In general, microfibers had a 
porous structure as it is also commonly observed for unloaded PLA electrospun fibers.49 
The presence of longitudinal striations was also usual in most of the prepared samples 
(Fig. 4, see red arrows). Surface became smoother when TCS was loaded since pores 
were less defined in the ternary drug loaded systems (Figures 4g and 4h) and even 
difficult to detect in the binary drug-loaded fibers (Figure 4c and 4d). CUM loaded 
samples were also characterized by the presence of embedded crystals (withe arrows), 
which highlighted the difficulty of p-coumaric molecules to mix with the PLA matrix. 
Nevertheless, these crystals were hardly detected in the ternary drug-loaded systems 
although their fibers usually had the lowest diameter values. This may be an indication 
of improved mixing with PLA in the presence of the other two drugs (TCS and KTP). 
 
[FIGURE 4] 
FTIR analysis of electrospun drug loaded samples 
PLA is a semicrystalline polymer that exhibits polymorphism, with different crystalline 
arrangements dependent on the crystallization conditions having been described.30,35 
Usually, the polymer crystallizes in a 107 helical conformation that gives rise to the so-
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called -,69-71 ’-72 and ’’-73 forms and the -crystals74 when the polymer is complexed 
with solvents like dimethylformamide. Furthermore, PLA can adopt a 32 molecular 
conformation as reported for 75,76 and 77 structures prepared by stretching or epitaxial 
crystallization. Nevertheless, PLA hardly crystallizes under usual processing conditions, 
and therefore no crystallization peaks are usually observed in DSC cooling traces from 
the melt or even during a subsequent heating run. Thus, commercial semicrystalline 
samples are obtained after subjecting samples to an annealing process which favors 
crystallization. It has been reported that the electrospinning technique facilitates 
molecular orientation; hence, the derived microfibers can be easily cold crystallized 
during a subsequent heating run. This final molecular orientation should depend on 
solution properties like viscosity, operational parameters (e.g. flow rate and applied 
voltage), diameter of electrospun fibers and even the presence of drugs that could act as 
nucleating agents.34 
FTIR spectroscopy can give information on molecular conformation and crystallinity 
although interpretation is difficult for PLA due to its different molecular conformations 
and packing arrangements. Nevertheless, several observations can be made: a) The 
absorbance of the carbonyl band around 1753 cm-1 has a smaller correlation with 
conformational changes of the main chain. Hence, this band can be used as the reference 
band to correct absorbance fluctuations due to differences in scaffold thickness;78 b) 
comparison between absorbance of bands at 1263 cm-1 ( (CH) +  (C-O-C) for a 
random conformation) and 1209 cm-1 (as (C-O-C) + ras (CH3) for a 107 helical 
conformation) has been reported to be highly relevant because bands should decrease 
and increase, respectively, when molecules adopt the more ordered helical 
conformation;79 c) relative intensities between bands at 1387 cm-1 (s (CH3), amorphous 
form) and 1360 cm-1 ( (CH), semicrystalline form) and bands at 1134 cm-1 (rs (CH3)) 
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and 1092 cm-1 (as (C–O–C)) changed upon annealing of samples (i.e. when crystallinity 
increased). Specifically, the relative intensity of bands at 1360 cm-1 and 1134 cm-1 was 
increased;80 and d) the 921 cm−1 absorption band is characteristic of the -form and 
corresponds to the coupling of C-C backbone with CH3 rocking.81 
Figure 5 compares the FTIR spectra (1800-900 cm-1) of the two unloaded PLA 
electrospun samples and the PLA 2002D sample loaded with the different combinations 
of drugs. No significant differences (not shown) were detected between spectra of 
samples from the two PLA matrices independently of the loaded drugs. Therefore, the 
difference in stereoregularity (i.e. from 2 to 4.2 wt-% of D-lactide) was smaller than 
spectral sensitivity to chain randomness. On the contrary, spectra of both PLA 2002D 
and PLA 4032D (not shown) samples showed significant changes with respect to the 
above b-d points which clearly suggested an increase of crystallinity and the ratio of the 
107 helical conformation when, for example, PLA 2002D fibers were simultaneously 
loaded with different drugs (i.e. a decrease of 1263 cm-1 band and an increase of 1360 
cm-1 1209, 1134 and 921cm-1 bands were observed for all loaded samples except the 
single CUM loaded sample). 
[FIGURE 5] 
FTIR spectra were sufficiently sensitive to detect the presence of drugs despite the small 
amount loaded. Basically, multiple peaks were observed in the 1670-1470 cm-1 range 
where bands associated with carbonyl groups and aromatic rings should appear. These 
rings were common for the three loaded drugs (Figure 1), and consequently additional 
signals detected in the spectra of drug-loaded scaffolds were always quite similar (i.e. 
peaks inside the dashed  ellipsoids drawn  in Figure 5). 
Thermal analysis of drug-loaded electrospun samples 
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The slight difference in the D-lactide content (i.e. 4.2 wt-% compared to 2.0 wt-%) 
affected thermal properties significantly, as depicted in Table 3 for the commercial 
pellet samples, which were expressly subjected to an annealing process to increase 
crystallinity. DSC heating traces of the corresponding electrospun scaffolds (Figures 6a 
and 6b) revealed again differences between the two PLA grades and also interesting 
consequences of the different processing methods. It should be pointed out that after 
electrospinning samples became practically amorphous but could be easily cold 
crystallized during a subsequent heating run, reaching typical crystallinity values of 
commercial annealed samples. A cold crystallization peak was hardly observed in the 
heating run of samples cooled from the melt state (i.e. not subjected to a specific 
annealing treatment), as also previously reported.82,83 Therefore, the capability of the 
electrospinning technique to render highly aligned and oriented molecules able to easily 
cold crystallize has been postulated by different authors.34,82 
[TABLE 3] 
[FIGURE 6] 
DSC heating runs of drug-loaded samples are more complex, especially those of ternary 
drug-loaded systems (Figures 6c and 6d). The main thermal characteristics deduced 
from the loaded scaffolds (summarized in Table 3) allow the following general remarks 
to be made: 
a) The glass transition temperature decreases compared to that observed for the 
corresponding unloaded scaffolds, suggesting a plasticizing effect caused by the 
incorporation of the small drug molecules. In addition, the enthalpic relaxation peak 
tends to be supressed, in contrast with unloaded samples. Therefore, the compact 
arrangement characteristic of an equilibrium condition is less favored. 
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b) The melting peak temperature decreases dramatically compared to the value of 
unloaded scaffolds. Furthermore, this decrease is more and less significant for ternary 
and single drug-loaded scaffolds, respectively. In addition, multiple peaks could be 
observed for the more complex loaded systems. These features suggest that drugs can 
be partially incorporated into the crystalline structure and even lead to different degrees 
of perfection. It should be pointed out that the melting peaks could only be associated 
with the PLA polymer matrix because the melting temperatures of TCS and KTP were 
lower (55-57 ºC and 93-96 ºC, respectively), whereas p-coumaric acid melted at a 
clearly higher temperature (i.e. 208-217 ºC). 
c) Binary and ternary drug-loaded systems become highly crystalline after the 
electrospinning process. Note the reduced cold crystallization enthalpy and the high 
melting enthalpy (i.e. the relatively high Hm - Hc values). The degrees of crystallinity 
are clearly higher than determined from unloaded samples, suggesting a nucleating 
effect of incorporated drugs. This effect is more pronounced when the more regular 
PLA 4032D sample is used.84 Logically, all studied samples showed a degree of 
crystallinity after cold crystallization slightly lower than determined for the commercial 
annealed samples. The temperature of the cold crystallization peak tends to diminish for 
drug-loaded samples, suggesting again a nucleating effect of drugs. 
 
Drug release from binary and ternary drug-loaded PLA electrospun scaffolds  
Drug release from electrospun fibers in a given medium is intimately related to their 
morphology and crystallinity and to possible intermolecular interactions between drugs 
and the polymer matrix. Therefore, a quantitative release study was performed 
considering both PLA 2002D and PLA 4032D matrices and single, binary and ternary 
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drug-loaded systems. We selected a phosphate buffered saline (PBS) supplemented with 
ethanol to facilitate the delivery of highly hydrophobic molecules such as TCS, KTP 
and CUM and avoid the establishment of equilibrium conditions that typically limit 
their release when only PBS is employed.33 Specifically, Figure 7 points out this 
problem for all loaded samples since the release percentage was always lower than 10%. 
Logically, drug release was enhanced by increasing the EtOH ratio, being a fast delivery 
with a high release percentage (i.e. between 60% and 90%) found for the PBS:EtOH 3:7 
v/v mixture. Experiments performed using a standard medium containing serum 
revealed an enhanced release with respect to PBS. Nevertheless,  this release was 
clearly lower than determined for PBS:EtOH 3:7 v/v since diffusion of aqueous serum 
within the microfibers was no possible. Therefore, results obtained with the PBS:EtOH 
may be useful to better appreciate the effect of changing matrix characteristics and load 
system. 
Figures 7a and 7b show the release profile of CUM from the single drug-loaded PLA 
2002D and PLA 4032D scaffolds in PBS:EtOH 3:7 v/v medium, respectively. It can be 
observed that a higher release percentage was attained from the less stereoregular PLA 
matrix (i.e. 80% compared to 60%), indicating that CUM was better retained in the 
presence of polymer crystalline domains. In any case, the release of CUM was very fast 
and reached values of 60-50% after only one hour of exposure to the medium. 
[FIGURE 7] 
Figures 7c-7h show the release profiles of TCS, KTP and CUM in PBS:EtOH 3:7 v/v 
medium from the binary and ternary drug-loaded systems. The following observations 
can be made: a) The release profiles for a given scaffold are similar for the three dugs 
independently of the PLA grade and the kind of system (binary or ternary); b) the 
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maximum release percentage is always greater from PLA 2002D scaffolds than from the 
corresponding PLA 4032D scaffolds; c) release percentages increase slightly when 
more drugs are simultaneously loaded in PLA 4032D scaffolds (i.e. 60%, 60-70% and 
80% for CUM in single, binary and ternary drug-loaded scaffolds, respectively), 
whereas percentages remain practically constant for PLA 2002D scaffolds. A slight 
synergic effect that increased the release seems to exist in complex systems and 
matrices that had higher encapsulation efficiency (e.g. PLA 4032D). This is interesting 
since it suggests that binary and ternary drug-loaded scaffolds have greater availability 
for their local action in the host tissue. 
Release rates can be quantitatively compared considering postulated theoretical kinetic 
models in order to fit the experimental release profiles. Release generally occurs in two 
different steps, with the fast release initially observed (0-60%) being well-described by 
the Higuchi equation: 
Mt ⁄ M0 = kH t(1⁄2)                    (0 ≤ Mt ⁄ M0 ≤ 0.6)    (1) 
where kH is the Higuchi release constant, Mt is the percentage of drug released at time t 
and M0 is the drug equilibrium percentage (considered as the maximum drug 
percentage).85,86 This model wa basically conceived for planar systems, but was then 
extended to different geometrics and porous systems. 
Table 4 summarizes the values of kH determined for CUM from the loaded scaffolds. 
The results show small differences in the release rate but no specific trend linked to the 
degree of crystallinity, fiber diameter and complexity of the system (single, binary or 
ternary) can be derived, probably due to the multiple factors with different impact on 
molecular diffusion that are involved. 
[TABLE 4]  
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Antibacterial properties of single, binary and ternary CUM loaded electrospun 
scaffolds 
Bacterial growth curves for E. coli (Figures 8a and 8b) and M. luteus (Figures 8c and 
8d) in the presence of unloaded and single, binary and ternary drug-loaded scaffolds of 
PLA 2002D and PLA 4032D were evaluated as an indication of the bactericide activity 
of loaded matrices. 
[FIGURE 8] 
Results clearly indicate that bacterial growth was inhibited for both binary and ternary 
TCS loaded scaffolds. This is a consequence of the well-known ability of TCS to block 
the active site of the enoyl-acyl carrier protein reductase enzyme, which is essential in 
the synthesis of fatty acids in bacteria.87 Thus, after 24 hours of culture, E. coli and M. 
luteus bacterial growths were 8-10% and 10-12% of the corresponding growths 
determined for the positive control, respectively. Curves were essentially independent of 
the polymer matrix and the additional incorporation of CUM and KTP. It seems that 
sufficient release was achieved by the high TCS content of scaffolds (i.e. 3 w/v-%) to 
inhibit bacterial growth. Also, this effect could not be improved by the presence of the 
other two drugs and was not influenced by morphology and crystallinity changes of 
electrospun scaffolds.  
Figure 8 also shows typical bacterial growth curves for single CUM loaded scaffolds. 
Thus, after an initial lag phase (4-5 hours), an exponential phase associated with binary 
fission was observed during which Gram-negative and Gram-positive bacterial growth 
stopped at a value close to 90% with respect to that found for the positive control. More 
interestingly, binary KTP/CUM loaded scaffolds showed moderate inhibition that was 
slightly dependent on the PLA grade and the type of bacteria. Specifically, growth 
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percentages decreased compared to the positive control to 40% and 50% for Gram-
negative bacteria grown on matrices based on PLA 2002D and PLA 4032D, 
respectively, and to 50% and 60% for Gram-positive bacteria grown on matrices based 
on PLA 2002D and PLA 4032D, respectively. From these results two conclusions can 
be drawn: a) KTP has a bacteriostatic effect with a not yet fully clarified 
mechanism,88,89 and b) the less stereoregular PLA matrix has a higher inhibition effect, 
in agreement with the enhanced drug release (Figures 8c and 8d).  
Bactericide activity was also evaluated by quantification of bacterial adhesion, as shown 
in Figure 9. Single CUM loaded scaffolds had a similar percentage of bacterial adhesion 
to the positive control, as expected from the bacterial growth results. In the same way, 
practically complete inhibition of bacterial adhesion was found for TCS/CUM and 
TCS/KTP/CUM loaded scaffolds. Intermediate adhesion values were obtained for 
binary KTP/CUM loaded scaffolds, with significant differences again being observed 
depending on the PLA grade. Thus, adhesions of 40% and 70% were determined for 
PLA 2002D (Figure 9a) and PLA 4032D (Figure 9b) scaffolds. The higher percentage 
found for the latter is in agreement with the differences in the release and bacterial 
growth. Adhesion results were similar for both Gram-negative and Gram-positive 
bacteria. 
[FIGURE 9] 
Cell viability of single, binary and ternary CUM loaded electrospun scaffolds 
Figure 10 illustrates cell adhesion and proliferation behavior of two epithelial cell lines 
(MDCK and VERO) in loaded PLA 2002D and PLA 4032D electrospun scaffolds. A 
good cell response was expected for CUM and KTP according to their antioxidant and 
anti-inflammatory activity, respectively. MDCK and VERO cell lines were selected for 
24 
 
their epithelial morphology and typical adherent growth which leads to formation of cell 
monolayers highly sensitive to cell damage due to their flake detachment from the 
culture plate. 
[FIGURE 10] 
Scaffolds loaded with 3 w/v-% of TCS were used as negative controls since this 
concentration was previously found to be cytotoxic for loaded PLA scaffolds.34 Cell 
adhesion on these scaffolds decreased to 20-30% compared to unloaded PLA scaffolds 
(positive control) after 24 h of culture. Note that this significant difference (p<0.001) 
was independent of the PLA grade (Figures 10a and 10b). It is highly interesting that 
incorporation of CUM reduced cell damage caused by TCS and favored cell viability. 
Thus, cell adhesion on binary TCS/CUM loaded scaffolds was increased by ca. 30% 
with respect to the negative control. Anti-inflammatory KTP had a similar, additive 
effect. In this way, cell adhesion on ternary TCS/KTP/CUM loaded scaffolds clearly 
increased and reached the same values as positive unloaded scaffolds and also as single 
drug-loaded PLA scaffolds (Figures 10a and 10b). 
Adhered cells kept their proliferative activity and ultimately were able to colonize the 
material, forming a monolayer tissue. Figures 10c and 10d show the quantification of 
cell growth, which was clearly related to the previous cell adhesion event. The cytotoxic 
effect of TCS can be reverted by the renewal of culture medium. Thus, cell viability 
increased, as demonstrated by values of 40% and 50% determined with respect to the 
unloaded scaffolds after 7 days of culture, which were higher that the above adhesion 
percentages. Nevertheless, viability was still significantly lower (p<0.01) than 
determined for the control. Again, positive effects on cell proliferation (p>0.95) were 
found for binary TCS/CUM loaded scaffolds compared to the negative TCS loaded 
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control, resulting in an increase in cell viability up to 80%. This represents an increase 
close to 30% with respect to the viable cells measured in single TCS loaded scaffolds. 
Cell proliferation in ternary TCS/KTP/CUM loaded scaffolds was similar to that of 
positive controls, as expected from the cell adhesion results, demonstrating that cell 
damage caused by TCS could be neutralized by the positive effect on cell viability 
caused by the incorporation of CUM and KTP. Finally, it should be indicated that no 
significant differences were observed between scaffolds prepared from the two PLA 
grades despite slight differences in drug release. 
CONCLUSIONS 
Bactericide, anti-inflammatory and antioxidant drugs like triclosan, ketoprofen and p-
coumaric acid, respectively, could be simultaneously loaded into PLA microfibers by 
the electrospinning technique. Porous and continuous microfibers with a unimodal 
diameter distribution could be prepared from a 10 w/v-% solution of PLA in a 
chloroform:acetone:dimethylsulfoxide mixture and using electrospinning parameters of 
15 kV, 12.5 cm and 5-10 mL/h for voltage, tip-collector distance and flow rate, 
respectively. 
Electrospun scaffolds had highly variable crystallinity which depended slightly on the 
PLA grade (at least when D-lactide content varied only from 4.2 to 2.0 wt-%) and 
strongly on the incorporated drugs. Thus, drugs seemed to produce a nucleating effect 
that, in some cases, led to crystallization levels like those of commercial annealed 
samples even for binary drug-loaded systems. Drug-loaded scaffolds also showed a 
decrease in the glass transition temperature that favored molecular diffusion processes 
and a decrease in the melting temperature as a consequence of incorporation of drugs in 
amorphous and crystalline phases, respectively. 
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The three drugs were released in a similar and fast way from a given scaffold (i.e. for a 
selected PLA matrix and a single, binary or ternary drug-loaded system) in a 
PBS:ethanol medium that mimics a typical serum supplemented PBS medium. In all 
cases, a significant amount of drug was retained inside PLA microfibers, especially the 
more stereoregular polymer. The entrapping efficiency of PLA was limited and the 
release of a specific drug seemed to increase with the complexity of the system (i.e. 
from single to ternary drug-loaded scaffolds), suggesting a synergic effect. New 
multifunctional scaffolds appear highly interesting since, besides imparting their 
expected and specific properties (i.e. antioxidant and anti-inflammatory), KTP and 
CUM can neutralize the cytotoxic effect caused by a moderate/high triclosan load. In 
summary, multifunctional PLA scaffolds with both high cell viability and protection 
against microorganisms can be easily prepared by the electrospinning technique.  
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FIGURE CAPTIONS 
 
Figure 1. Chemical structures of polylactide (PLA 2002D and PLA 4032D), triclosan 
(TCS), p-coumaric acid (CUM) and ketoprofen (KTP). 
Figure 2. Low magnification SEM micrographs of PLA 2002D + CUM (a), PLA 
4032D + CUM (b), PLA 2002D + TCS/CUM (c), PLA 4032D + TCS/CUM (d), PLA 
2002D + KTP/CUM (e), PLA 4032D + TCS/CUM (f), PLA 2002D + TCS/KTP/CUM 
(g) and PLA 4032D + TCS/KTP/CUM (h) samples. 
Figure 3. Diameter distribution of PLA + CUM (a), PLA + KTP/CUM (b), PLA + 
TCS/CUM (c) and PLA + TCS/KTP/CUM (d) electrospun microfibers. 
Figure 4. High magnification SEM micrographs of PLA 2002D + CUM (a), PLA 
4032D + CUM (b), PLA 2002D + TCS/CUM (c), PLA 4032D + TCS/CUM (d), PLA 
2002D + KTP/CUM (e), PLA 4032D + TCS/CUM (f), PLA 2002D + TCS/KTP/CUM 
(g) and PLA 4032D + TCS/KTP/CUM (h) samples. Dashed arrows point to longitudinal 
striations whereas CUM crystals are indicated by white arrows. 
Figure 5. FTIR spectra (1800-900 cm-1 region) of PLA 2002D, PLA 4032D, PLA 
2002D + CUM, PLA 2002D + TCS/CUM, PLA 2002D + KTP/CUM and PLA 2002D + 
TCS/KTP/CUM electrospun scaffolds. Wavenumbers of main peaks are labelled. 
Figure 6. DSC heating runs (20 ºC/min) of PLA 2002D (a), PLA 4032D (b), PLA 
2002D + TCS/KTP/CUM (c) and PLA 4032D + TCS/KTP/CUM (d) electrospun 
scaffolds. 
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Figure 7. Release curves in PBS:EtOH (black symbols), PBS supplemented with serum 
(red symbols), PBS (blue symbols) media of CUM (a,b), TCS/CUM (c,d), KTP/CUM 
(e,f) TCS/KTP/CUM (g,h) loaded PLA 2002D (a,c,e,g) and PLA 4032D (b,d,f,h) 
electrospun scaffolds. 
Figure 8. Relative growth of Escherichia coli (a,b) and Micrococcus luteus (c,d) on 
binary and ternary drug-loaded PLA 2002D (a,c) and PLA 4032D (b,d) electrospun 
scaffolds.  
Figure 9. Escherichia coli (blue) and Micrococcus luteus (pink) adhesion on a 
polystyrene plate as positive control and single, binary and ternary drug-loaded PLA 
2002D (a) and PLA 4032D (b) electrospun scaffolds (*p<0.05 vs. control, ANOVA-
Tukey test).  
Figure 10. Adhesion (a,b) and proliferation (c,d) of MDCK (blue) and VERO (red) 
cells on a polystyrene plate as positive control and TCS, CUM, TCS/CUM, KTP/CUM 
and TCS/KTP/CUM PLA 2002D (a,b) and PLA 4032D (c,d) electrospun scaffolds 
(†p<0.05; ‡p<0.01 vs. positive, ANOVA-Tukey test). 
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Table 1. Electrospun of scaffolds loaded with active agents.a  
Electrospun Polymer Solvent Concentration Active Agent 
Bactericide loaded systems   
PCL/PLA CF/acetone  2:1v/v 10 w/v-% Triclosan 34 
PLA CF/DMF 9:1 v/v 8 w/v-% Triclosan 39 
CA DMF 3 wt-% Chlorhexidine 40 
PAN DMSO 15 wt-% QACs 41 
CA/PEU DMF/THF 50:50 v/v 20/10 wt-%  PHMB 42 
PAN DMF 10 w/v-% PHMB 43 
PAN DMF 10 wt-%  N-Halamine 44 
PEO/Chitosan H2O/Acetic acid 3-4 wt-% K5N8Q 45  
PDLLA, PEO DMF 20–24 wt-% Antibacterial 
peptides 46 
PADAS HFIP 10 wt-% Chlorhexidine 47 
PLA/PCL CF-acetone 2:1 v/v 10-2.5 wt-% Triclosan 48 
PLA/PEG DCM/DMF 70:30 v/v 7-35 wt-% Triclosan 49 
PHB/PEO DMF/CF  80:20 v/v 10 wt-% Chlorhexidine 50 
Anti-inflammatory loaded systems 
PVP DMAc/ethanol 1:9 v/v 10 wt-% Ketoprofen 51 
EC (ethyl cellulose) ethanol 12.5wt-%  Ketoprofen 38 
PVA Deionized water 5 wt-% Ketoprofen 52 
PCL CF/methanol 3:1 v/v 3-17 wt-% Curcumin 53 
PCL CF/DMF 3:1 v/v 5.7 wt-% Dexamethasone 54 
PLA DCM/DMF 62.5:37.5 v/v 5.7 wt-% Dexamethasone 41
PLGA DCM 1-10 wt-% Ibuprofen 55 
PCL acetone 0.5-5 wt-% Diclofenac sodium 56 
PAM14 Ethanol or Acetic Acid 2 wt-% Diclofenac sodium 57 
PLA, PLA/PEG DMF/DMSO 3:1 w/w 30 wt-% Diclofenac sodium 58 
Antioxidant loaded systems 
PCL DCM/DMF 1:1 v/v 2.5-10 wt-% Resorcinol 59 
CA Acetone/DMAc 2:1 v/v 5 wt-% Vitamin E 60 
CA Acetone/DMAc 2:1 v/v 0.5 wt-% Vitamin A 47 
PLA DMF/DMSO 9:1 v/v 9.1 wt-% Vitamin B6 30 
PLA DMF/DMSO 9:1 v/v 9.1 wt-% Polyphenols 48 
PCL CF/methanol 3:1 v/v 3-17wt-% Curcumin 40 
PLLA DCM/DMF 7:3 v/v 28.6 wt-% Gallic Acid 61 
PCL CF/ethanol 3:1 w/w 4-10 wt-% Resveratrol 62 
a PCL (poly(-caprolactone)), PLA (polylactide), PDLLA (poly(D,L-lactide)), PEG  
(poly(ethylene glicol)), CA (cellulose acetate), PAN (polyacrylonitrile), PEU (poly (ester urea)), 
PEO (poly(ethylene oxide)), PADAS (poly(ester amide) derived from alanine, 1,12-
dodecanediol and sebacic acid units), QACs (N,N-didecyl-N,N-dimethylammonium chloride 
and bis-(3-aminopropyl)-dodecylamine), PHMB (polyhexamethylenebiguanide hydrochloride),  
K5N8Q (potassium 5-nitro-8-quinolinolate), DMF (N,N-dimethylformamide), DMSO (dimethyl 
sulfoxide), THF (tetrahydrifurane), HFIP (hexafluoroisopropanol), PHB 
(poly(hydroxybutyrate)), CF (Chloroform), DCM (dichloromethane). PAM14 (poly(maleic 
anhydride-alt-2-methoxyethyl vinyl ether)). DMAc (N,N-dimethylacetamide). 
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Table 2. Diameters of unloaded and drug loaded electrospun PLA fibers. 
Sample Diametera,b (m) 
PLA 2002D 1.86 ± 0.06 
PLA 4032D 1.66 ± 0.05 
PLA 2002D + CUM 3.85 ± 0.01 
PLA 4032D + CUM 2.14 ± 0.03 
PLA 2002D + TCS/CUM 3.23 ± 0.01 
PLA 4032D + TCS/CUM 1.92 ± 0.06 
PLA 2002D + KTP/CUM 2.28 ± 0.01 
PLA 4032D + KTP/CUM 1.82 ± 0.03 
PLA 2002D + TCS/KTP/CUM 2.54 ± 0.01 
PLA 4032D + TCS/KTP/CUM 1.70 ± 0.01 
 
aFibers were obtained using same electrospinning operational 
parameters: applied voltage of 15 kV, tip-collector distance of 
12.5 cm and flow rate of 10 mL/h except for ternary drug-
loaded fibers that decreased to 5 mL/h. 
bMean value ± standard deviation.  
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Table 3. Selected calorimetric data from the heating scan performed with the different PLA electrospun samples. 
 
 
 
 
aData obtained from commercial pellet samples. 
bValues have been rescaled considering the theoretical content of TCS (i.e. 3 w/v-%) , KTP (i.e. 1 w/v-%) and CUM (i.e. 1 w/v-%). 
cShoulders are rather frequent at a lower temperature than that indicated for the predominant melting peak. 
dDetermined by considering an estimated melting enthalpy of 106 J/g for a 100% crystalline sample.83,84 Left and right values 
correspond to crystallinities deduced for the as electrospun material (i.e. considering ΔHm - ΔHc as the enthalpy associated to crystalline 
phase of the electrospun sample) and those attained after cold crystallization (i.e. considering ΔHm as the enthalpy associated to the final 
crystalline phase), respectively. 
eTwo predominant peaks were clearly detected. The most intense is in this case indicated by bold characters. 
 
 
Sample Tg 
(ºC) 
Tc 
(ºC) 
Hcb
(J/g) 
Tm c
(ºC) 
Hmb
(J/g) 
Hm- Hcb
(J/g) 
 
cd
PLA 2002Da 59.6 - - 149.3 29.2 29.2 0.28 
PLA 2002D 59.3 106.0 18.5 146.4 26.1 7.6 0.07, 0.25 
PLA 4032Da 69.3 - - 167.0 35.0 35.0 0.33 
PLA 4032D 62.4 100.2 22.6 165.9 30.8 8.2 0.08, 0.29 
PLA 2002D + CUM 54.2 94.6 24.0 136.5 24.1 0.1 0.00. 0.27 
PLA 4032D + CUM 55.0 75.1 24.5 156.3 31.7 7.2 0.07, 0.30 
PLA 2002D + TCS/CUM 48.6 92.7 6.1 132.2 21.5 15.4 0.16, 0.22 
PLA 4032D + TCS/CUM 44.1 65.9 10.2 147.2 28.9 18.7 0.19, 0.27 
PLA 2002D + KTP/CUM 43.5 60.0 5.2 112.9 28.1 22.9 0.22, 0.27 
PLA 4032D + KTP/CUM 44.2 52.2 3.8 138.9 28.2 24.4 0.25, 0.29 
PLA 2002D + TCS/KTP/CUM 43.0 93.1 2.6 122.8 13.5 10.9 0.10, 0.13 
PLA 4032D + TCS/KTP/CUM 43.0 - - 122.7, 126.1e 18.6 18.6 0.18 
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Table 4. Higuchi kinetic constant and correlation factor for the first part (0-60%) of the 
CUM release from the different loaded scaffolds.  
 
Sample kH (h-0.5) r 
PLA 2002D + CUM 0.76 0.989 
PLA 4032D + CUM 0.69 0.990 
PLA 2002D + TCS/CUM 0.57 0.990 
PLA 4032D + TCS/CUM 0.72 0.986 
PLA 2002D + KTP/CUM 1.07 0.991 
PLA 4032D + KTP/CUM 0.89 0.982 
PLA 2002D + TCS/KTP/CUM 0.41 0.985 
PLA 4032D + TCS/KTP/CUM 0.67 0.998 
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FIGURE 2 
Llorens et al. 
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FIGURE 3 
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FIGURE 5 
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FIGURE 6 
Llorens et al. 
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FIGURE 7 
Llorens et al. 
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FIGURE 8 
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FIGURE 9 
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FIGURE 10 
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